Sanuwave Health price target raised to $54 from $49 at Roth Capital

Roth Capital analyst Kyle Bauser raised the firm’s price target on Sanuwave Health (SNWV) to $54 from $49 and keeps a Buy rating on the shares. The company reported Q2 results that were in line with the company’s preliminary sales announcement, the analyst tells investors in a research note. With the commercial team built out, the updated manufacturing process for its applicator on track for completion in 4Q25, and favorable adoption/awareness of UltraMIST within the provider community, Roth expects strong sales growth and earnings leverage to continue, the firm added.